INmune Bio Q1 net loss narrows on lower R&D expenses

INmune Bio, Inc.

INmune Bio, Inc.

INMB

0.00


Overview

  • US immunology developer's Q1 net loss narrowed year-over-year on lower R&D expenses

  • Company reported no revenue for Q1, down from minimal revenue a year earlier

  • Company expects CORDStrom regulatory filings in UK and EU later in 2026


Outlook

  • INmune Bio expects to submit CORDStrom MAA to UK MHRA in mid-summer 2026

  • Company anticipates CORDStrom BLA submission to FDA in Q4 2026

  • Additional imaging analyses from MINDFuL trial with XPro in Alzheimer's expected soon


Result Drivers

  • LOWER R&D EXPENSES - Net loss narrowed mainly due to reduced research and development spending


Company press release: ID:nGNX2Q02d3


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q1 EPS

-$0.20


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for INmune Bio Inc is $7.50, about 393.4% above its May 6 closing price of $1.52


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.